Case Study
Embedded Qualitative Patient Interviews Support Regulatory Approval of Novel Oncology Treatment
Discover how Evidera’s Patient-Centered Research team helped to conduct embedded qualitative interviews that provided insights to lessen regulatory concerns about treatment side effects.
Read More
Case Study
Real-World Data Insights from LiveTracker® Determine Prescribing Trends for Cancers with High PD-L1 Protein Expression
Evidera's Real-World Data Solutions team used LiveTracker to evaluate HCP-reported data on treatment patterns in patients with non-small cell lung cancer and melanoma.
Read More
Case Study
Oncology Developer Utilizes Integrated Scientific Advice to Optimize Phase III Trial, Aligning Regulator and HTA Needs
Gain insight into how Evidera’s Value & Development Consulting team leveraged our Integrated Scientific Advice (ISA) offering to provide feedback to drug developers to optimize their evidence generation plans and satisfy stakeholder requirements.
Read More
Case Study
Six-Year Collaboration Across Six Indications for Groundbreaking Oncology Therapy
Evidera's Evidence Synthesis, Modeling & Communication team generated integrated packages of evidence, including value messaging, systematic reviews and comparative effectiveness analyses, and economic models, for six indications.
Read More
Case Study
Virtual Expanded Access Program Providing Breast Cancer Patients Early Access to Treatment During the COVID-19 Pandemic
Evidera was able to provide a virtual approach to mitigate the risk to patient safety during the COVID-19 pandemic and enabled early patient access to 400 US breast cancer patients ahead of commercial availability.
Read More
Case Study
Enhancing Oncology Market Access with a Real-World Evidence EAMS Add-on
Discover how Evidera researchers designed an observational study to conceptualize and implement real-world data collection in an Early Access to Medicines Scheme (EAMS) for an oncology therapy.
Read More
Case Study
Evidera Led Effort to Qualify the First Biomarker for COPD Trial Enrichment
Learn how Evidera's partnership with the COPD Foundation Biomarker Qualification Consortium led to the qualification of plasma fibrinogen as the first biomarker in COPD for enrichment of clinical trials by the FDA.
Read More